These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28614091)

  • 1. Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo.
    Carruthers J; Solish N; Humphrey S; Rosen N; Muhn C; Bertucci V; Swift A; Metelitsa A; Rubio RG; Waugh J; Quiring J; Shears G; Carruthers A
    Dermatol Surg; 2017 Nov; 43(11):1321-1331. PubMed ID: 28614091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study.
    Bertucci V; Humphrey S; Carruthers J; Solish N; Muhn C; Swift A; Rubio RG; Shears G; Rosen N
    Dermatol Surg; 2017 Dec; 43 Suppl 3():S262-S273. PubMed ID: 33065952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
    Bertucci V; Solish N; Kaufman-Janette J; Yoelin S; Shamban A; Schlessinger J; Snyder D; Gallagher C; Liu Y; Shears G; Rubio RG
    J Am Acad Dermatol; 2020 Apr; 82(4):838-845. PubMed ID: 31791824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).
    Carruthers JD; Fagien S; Joseph JH; Humphrey SD; Biesman BS; Gallagher CJ; Liu Y; Rubio RG; ;
    Plast Reconstr Surg; 2020 Jan; 145(1):45-58. PubMed ID: 31609882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
    Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
    Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
    J Drugs Dermatol; 2020 Oct; 19(10):985-991. PubMed ID: 33026771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.
    Solish N; Carruthers J; Kaufman J; Rubio RG; Gross TM; Gallagher CJ
    Drugs; 2021 Dec; 81(18):2091-2101. PubMed ID: 34787840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.
    Li X; Sui C; Xia X; Chen X
    Aesthetic Plast Surg; 2023 Feb; 47(1):365-377. PubMed ID: 36097079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study.
    Fabi SG; Cohen JL; Green LJ; Dhawan S; Kontis TC; Baumann L; Gross TM; Gallagher CJ; Brown J; Rubio RG
    Dermatol Surg; 2021 Jan; 47(1):48-54. PubMed ID: 32773446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
    De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
    Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
    Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
    J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
    Carruthers JA; Lowe NJ; Menter MA; Gibson J; Nordquist M; Mordaunt J; Walker P; Eadie N;
    J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
    Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids.
    Carruthers A; Carruthers J
    Dermatol Surg; 2005 Oct; 31(10):1297-303. PubMed ID: 16188182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
    Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.